Hims & Hers Health Executive Compensation (FY25)
HIMS · Executive and director compensation, fiscal 2022 to 2025
The paid brief on Hims & Hers Health
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 20, 2026Latest filing (8-K): June 15, 2026
9 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
342 figures on this page: 337 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
More on Hims & Hers Health
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Andrew Dudum: $24,609,077 → $22,958,907 (6.7% lower)
CEO pay ratio: 309:1 → 272:1 (12.0% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Hims & Hers Health's chief executive and what were they paid?
Andrew Dudum, Chief Executive Officer and Chairman, received $22,958,907 in total compensation for fiscal 2025. Dudum's total was 6.7% lower than the $24,609,077 reported for fiscal 2024.
What was Hims & Hers Health's say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 99.3% of votes cast for or against in favor at the meeting held June 11, 2026.
Which companies are in Hims & Hers Health's peer group?
The disclosed peer group names Alteryx, Apollo Medical, Box, Bumble and CarGurus, among others.
What is Hims & Hers Health's chief executive pay ratio?
The company reported a chief executive pay ratio of 272:1 for fiscal 2025, against median employee compensation of $84,402.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Andrew Dudum Chief Executive Officer and Chairman | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Oluyemi Okupe Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Melissa Baird Chief Operating Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Michael Chi Chief Marketing Officer | ◇ | — | ◇ | ◇ | ◇ | — | — | ◇ |
Soleil Boughton Chief Legal Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Irene Becklund Former Interim Principal Financial Officer Departed during or after this year Served on an interim basis | ◇ | — | ◇ | — | — | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Andrew Dudum Chief Executive Officer and Chairman | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Yemi Okupe Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Melissa Baird Chief Operating Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Mike Chi Chief Commercial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Soleil Boughton Chief Legal Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Andrew Dudum Chief Executive Officer and Chairman | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Melissa Baird Chief Operating Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Yemi Okupe Chief Financial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Mike Chi Chief Commercial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Soleil Boughton Chief Legal Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Mohamed Elshenawy Chief Technology Officer | ◇ | ◇ | ◇ | — | ◇ | — | — | ◇ |
Andrew Dudum Chief Executive Officer and Chairman | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Nader Kabbani Former Chief Operating Officer Departed during or after this year | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Yemi Okupe Chief Financial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Melissa Baird Former Chief Operating Officer | ◇ | — | ◇ | — | — | — | ◇ | ◇ |
Mike Chi Chief Operating Officer (previously Chief Commercial Officer) | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Soleil Boughton Chief Legal Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Andrew Dudum | RSU | — | — | — | ◇ | — | — | ◇ |
| Andrew Dudum | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Andrew Dudum | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Andrew Dudum | OPTION | — | — | — | ◇ | — | ◇ | ◇ |
| Melissa Baird | RSU | — | — | — | ◇ | — | — | ◇ |
| Melissa Baird | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Melissa Baird | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Mohamed Elshenawy | RSU | — | — | — | ◇ | — | — | ◇ |
| Mr. Chi | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Mr. Chi | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Mr. Chi | RSU | — | — | — | ◇ | — | — | ◇ |
| Mr. Okupe | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Mr. Okupe | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Mr. Okupe | RSU | — | — | — | ◇ | — | — | ◇ |
| Nader Kabbani | RSU | — | — | — | ◇ | — | — | ◇ |
| Soleil Boughton | RSU | — | — | — | ◇ | — | — | ◇ |
| Soleil Boughton | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Soleil Boughton | RSU | ◇ | — | — | ◇ | — | — | ◇ |
Fiscal 2022, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Soleil Boughton | RSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/24/22 | |
| Option | ◇ | — | ◇ | 3/1/23 | |
| Andrew Dudum | RSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/24/22 | |
| Option | ◇ | — | ◇ | 3/1/23 | |
| Nader Kabbani | RSU | ◇ | ◇ | — | — |
| Yemi Okupe | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/24/22 | |
| Option | ◇ | — | ◇ | 3/1/23 | |
| Mohamed Elshenawy | RSU | ◇ | ◇ | — | — |
| Melissa Baird | RSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/24/22 | |
| Option | ◇ | — | ◇ | 3/1/23 | |
| Mike Chi | PSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/24/22 | |
| Option | ◇ | — | ◇ | 8/9/32 | |
| Option | ◇ | — | ◇ | 3/1/23 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Andrew Dudum
Chief Executive Officer and Chairman · Terms as described in the company’s compensation discussion · citing a 2025 filing
| Severance multiple | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
Melissa Baird
Former Chief Operating Officer · Terms as described in the company’s compensation discussion · citing a 2025 filing
| Severance multiple | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
Mohamed Elshenawy
Chief Technology Officer · Offer letter · citing a 2026 filing
| Equity acceleration on change in control | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
| Clawback | ◇ |
Yemi Okupe
Chief Financial Officer · Terms as described in the company’s compensation discussion · citing a 2025 filing
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Christopher Payne | ◇ | ◇ | — | — | — | — | ◇ |
Anja Manuel | ◇ | ◇ | — | — | — | — | ◇ |
Deb Autor | ◇ | ◇ | — | — | — | ◇ | ◇ |
Kåre Schultz | ◇ | ◇ | — | — | — | — | ◇ |
David Wells Lead independent director | ◇ | ◇ | — | — | — | — | ◇ |
Andrea Perez | ◇ | ◇ | — | — | — | — | ◇ |
Christiane Pendarvis | ◇ | ◇ | — | — | — | — | ◇ |
Patrick Carroll | ◇ | ◇ | — | — | — | — | ◇ |
Delos Cosgrove | ◇ | ◇ | — | — | — | — | ◇ |
Kofi Amoo-Gottfried and Andrew Dudum served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as restricted stock units.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Alteryx AYX
- Apollo Medical symbol not shown
- Box BOX
- Bumble BMBL
- CarGurus CARG
- Coursera COUR
- DigitalOcean DOCN
- Duolingo DUOL
- Elastic N.V. ESTC
- EngageSmart ESMT
- Five9 FIVN
- Jamf Holding JAMF
- PagerDuty PD
- Privia Health Group PRVA
- Rapid7 RPD
- SentinelOne S
- Smartsheet SMAR
- Sprinklr CXM
- Udemy UDMY
- Yelp YELP
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 11, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 12, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 6, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | June 1, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 2, 2022 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Hims & Hers Health disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Hims & Hers Health sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
342 figures on this page: 337 cited to the filing that reported them, 5 calculated from figures it prints.
337 cited to the filing
5 calculated from the filing
Documents cited
- 0001773751-26-000096
- 0001773751-26-0000602025 Summary Compensation Table · CEO Pay Ratio · Director Compensation · Exhibit · and 1 more section
- 0001773751-25-000211
- 0001773751-25-0001362024 Summary Compensation Table · Compensation Discussion and Analysis · Director Compensation
- 0001773751-24-000185
- 0001773751-24-0001102023 Summary Compensation Table
- 0001773751-23-000155
- 0001140361-23-0212762022 Summary Compensation Table
- 0001193125-22-170297
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Hims & Hers Health executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/HIMS (accessed 2026).
Short form: data: Velarion
The paid brief for Hims & Hers Health
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
9 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Hims & Hers Health and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Hims & Hers Health discloses
The companies named in HIMS's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}